サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1671096

血友病A治療の世界市場：市場規模・シェア・動向、業界分析 (治療の種類別・治療法の種類別・流通チャネル別・地域別)、将来予測 (2025年～2034年)

Hemophilia A Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, Therapy Type, Distribution Channel, and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 116 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
血友病A治療の世界市場：市場規模・シェア・動向、業界分析 (治療の種類別・治療法の種類別・流通チャネル別・地域別)、将来予測 (2025年～2034年)
出版日: 2025年02月01日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の血友病A治療の市場規模は2034年までに198億6,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

血友病A治療とは、血友病Aを管理・治療するための医療介入を指します。この遺伝性疾患では、血液凝固第VIII因子が十分でないため、血液凝固が困難になり、過剰出血のリスクが高まる。血友病Aの主な治療法は、遺伝子組換えまたは血漿由来の血液凝固因子補充療法によって不足する血液凝固因子を補充することです。

血友病A治療市場は、遺伝子治療、半減期延長血液凝固第VIII因子製剤、エミシズマブのような非因子補充療法など、治療オプションの進歩によって牽引されています。血友病とその管理に対する意識の高まりと医療投資の増加は、特に新興市場において治療へのアクセスを向上させています。

遺伝的な根本原因に対処し、皮下注射のような侵襲性の低い治療オプションによって患者のコンプライアンスを改善する革新的な治療法の開発には機会が存在します。注目すべき動向は、投与回数を減らすことができる半減期延長型第VIII因子製剤の開発です。さらに、非因子補充製剤や遺伝子編集技術など、革新的な治療法への多額の投資が市場の状況を形成しています。

血友病A治療市場：分析概要

治療の種類別では、出血エピソードを予防し患者のQOLを向上させる予防療法が血友病A治療市場で最大のシェアを占めています。特に若年患者を中心に、長期的な管理としてますます支持されています。

治療法の種類別では、第VIII因子製剤がオンデマンド治療・予防に広く使用されており、遺伝子組換え療法と血漿由来第VIII因子製剤が市場を独占しています。遺伝子治療とモノクローナル抗体は最も急速に成長しているセグメントであり、長期的な解決策を提供する可能性があります。

病院薬局は、急性期治療や緊急治療において重要な役割を担っているため、支配的な流通チャネルとなっています。専門薬局は、特に遺伝子治療やモノクローナル抗体のような先進治療薬で最も速い成長を記録しています。

北米は、確立された医療インフラと革新的な治療法の高い導入率に牽引され、最大の市場シェアを占めています。アジア太平洋地域は、医療アクセスの拡大、患者の意識向上、新興経済圏での投資増加などを背景に急成長しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 分析手法

第4章 血友病A治療市場の洞察

  • 市場スナップショット
  • 血友病A治療の市場力学
    • 促進要因と機会
      • 遺伝子治療の進歩
      • 半減期延長製品の採用
      • 非因子補充療法の台頭
    • 抑制要因と課題
      • 治療費の高騰
  • PESTLE分析
  • 血友病A治療市場の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の血友病A治療市場：治療の種類別

  • 主な調査結果
  • イントロダクション
  • オンデマンド
  • 治療
  • 予防

第6章 世界の血友病A治療市場：治療法の種類別

  • 主な調査結果
  • イントロダクション
  • 因子補充療法
  • デスモプレシン・フィブリンシーラント
  • 遺伝子治療・モノクローナル抗体

第7章 世界の血友病A治療市場：流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 専門薬局

第8章 世界の血友病A治療市場：地域別

  • 主な分析結果
  • イントロダクション
    • 血友病A治療市場の評価：地域別 (2020～2034年)
  • 北米
    • 北米：治療の種類別 (2020～2034年)
    • 北米：治療法の種類別 (2020～2034年)
    • 北米：流通チャネル別 (2020～2034年)
    • 米国
    • カナダ
  • 欧州
    • 欧州：治療の種類別 (2020～2034年)
    • 欧州：治療法の種類別 (2020～2034年)
    • 欧州：流通チャネル別 (2020～2034年)
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋：治療の種類別 (2020～2034年)
    • アジア太平洋：治療法の種類別 (2020～2034年)
    • アジア太平洋地域：流通チャネル別 (2020～2034年)
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：治療の種類別 (2020～2034年)
    • 中東・アフリカ：治療法の種類別 (2020～2034年)
    • 中東・アフリカ：流通チャネル別 (2020～2034年)
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：治療の種類別 (2020～2034年)
    • ラテンアメリカ：治療法の種類別 (2020～2034年)
    • ラテンアメリカ：流通チャネル別 (2020～2034年)
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • CSL Behring
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Sanofi（through its acquisition of Bioverativ）
  • F. Hoffmann-La Roche Ltd.
  • Octapharma AG
  • Grifols S.A.
  • BioMarin Pharmaceutical Inc.
  • Spark Therapeutics（a subsidiary of Roche）
  • Aptevo Therapeutics
  • Kedrion Biopharma
  • Sangamo Therapeutics
  • uniQure N.V.
図表

List of Tables:

  • Table 1 Global Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 2 Global Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 3 Global Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 4 North America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 5 North America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 6 North America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 7 US: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 8 US : Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 9 US : Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 10 Canada: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 11 Canada: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 12 Canada: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 13 Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 14 Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 15 Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 16 UK: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 17 UK: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 18 UK: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 19 France: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 20 France: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 21 France: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 22 Germany: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 23 Germany: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 24 Germany: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 25 Italy: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 26 Italy: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 27 Italy: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 28 Spain: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 29 Spain: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 30 Spain: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 34 Russia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 35 Russia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 36 Russia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 43 China: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 44 China: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 45 China: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 46 India: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 47 India: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 48 India: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 52 Japan: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 53 Japan: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 54 Japan: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 58 South Korea: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 59 South Korea: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 60 South Korea: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 61 Australia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 62 Australia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 63 Australia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 73 UAE: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 74 UAE: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 75 UAE: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 76 Israel: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 77 Israel: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 78 Israel: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 79 South Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 80 South Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 81 South Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 85 Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 86 Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 87 Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 88 Mexico: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 89 Mexico: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 90 Mexico: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 91 Brazil: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 92 Brazil: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 93 Brazil: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 94 Argentina: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 95 Argentina: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 96 Argentina: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Hemophilia A Treatment Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment Type
  • Figure 7. Global Hemophilia A Treatment Market, by Treatment Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Therapy Type
  • Figure 9. Global Hemophilia A Treatment Market, by Therapy Type, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Hemophilia A Treatment Market, by Distribution Channel, 2024 & 2034 (USD Billion)
目次
Product Code: PM1107

The global hemophilia A treatment market size is expected to reach USD 19.86 billion by 2034, according to a new study by Polaris Market Research. The report "Hemophilia A Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (On-Demand, Cure, and Prophylaxis), Therapy Type, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Hemophilia A treatment refers to the medical interventions used to manage and treat hemophilia A. In this genetic disorder, the blood lacks sufficient clotting factor VIII, leading to difficulty in blood clotting and an increased risk of excessive bleeding. The primary treatment for Hemophilia A involves replacing the missing clotting factor through factor replacement therapy, which can be either recombinant or plasma-derived.

The hemophilia A treatment market is driven by advancements in therapeutic options, including gene therapy, extended half-life factor VIII products, and non-factor replacement therapies like emicizumab. Growing awareness about hemophilia and its management, along with increasing healthcare investments, is enhancing access to treatments, particularly in emerging markets.

Opportunities exist in developing innovative therapies that address the genetic root causes and improve patient compliance through less invasive treatment options such as subcutaneous injections. A notable trend is the development of extended half-life factor VIII products, offering reduced dosing frequency. Additionally, significant investments in innovative therapies, including non-factor replacement products and gene-editing technologies, are shaping the market landscape.

Hemophilia A Treatment Market Report Highlights

Based on treatment type, prophylaxis holds the largest share in the hemophilia A treatment market due to its ability to prevent bleeding episodes and improve patient quality of life. It is increasingly favored for long-term management, particularly among younger patients.

By therapy type, the factor replacement therapy segment dominates the market, with recombinant and plasma-derived factor VIII products being widely used for on-demand treatment and prophylaxis. Gene therapy & monoclonal antibodies is the fastest-growing segment, offering potential long-term solutions.

Hospital pharmacies are the dominant distribution channel due to their critical role in acute care and emergency treatment. Specialty pharmacies are registering the fastest growth, particularly for advanced therapies like gene therapy and monoclonal antibodies.

North America holds the largest market share, driven by a well-established healthcare infrastructure and high adoption of innovative therapies. Asia Pacific is the fastest-growing region, fueled by expanding healthcare access, rising patient awareness, and increasing investments in emerging economies.

Polaris Market Research has segmented the hemophilia A treatment market report on the basis of treatment type, therapy type, distribution channnel, and region:

By Treatment Type Outlook (Revenue - USD Billion, 2020-2034)

  • On-Demand
  • Cure
  • Prophylaxis

By Therapy Type Outlook (Revenue - USD Billion, 2020-2034)

  • Factor Replacement Therapy
  • Desmopressin & Fibrin Sealants
  • Gene Therapy & Monoclonal Antibodies

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

  • Hospital Pharmacies
  • Specialty Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Hemophilia A Treatment Market Insights

  • 4.1. Hemophilia A Treatment Market - Market Snapshot
  • 4.2. Hemophilia A Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Advancements in Gene Therapy
      • 4.2.1.2. Adoption of Extended Half-Life Products
      • 4.2.1.3. Rise of Non-Factor Replacement Therapies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Treatments
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Hemophilia A Treatment Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Hemophilia A Treatment Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • 5.3. On-Demand
    • 5.3.1. Global Hemophilia A Treatment Market, by On-Demand, by Region, 2020-2034 (USD Billion)
  • 5.4. Cure
    • 5.4.1. Global Hemophilia A Treatment Market, by Cure, by Region, 2020-2034 (USD Billion)
  • 5.5. Prophylaxis
    • 5.5.1. Global Hemophilia A Treatment Market, by Prophylaxis, by Region, 2020-2034 (USD Billion)

6. Global Hemophilia A Treatment Market, by Therapy Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • 6.3. Factor Replacement Therapy
    • 6.3.1. Global Hemophilia A Treatment Market, by Factor Replacement Therapy, by Region, 2020-2034 (USD Billion)
  • 6.4. Desmopressin & Fibrin Sealants
    • 6.4.1. Global Hemophilia A Treatment Market, by Desmopressin & Fibrin Sealants, by Region, 2020-2034 (USD Billion)
  • 6.5. Gene Therapy & Monoclonal Antibodies
    • 6.5.1. Global Hemophilia A Treatment Market, by Gene Therapy & Monoclonal Antibodies, by Region, 2020-2034 (USD Billion)

7. Global Hemophilia A Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Hemophilia A Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.4. Specialty Pharmacies
    • 7.4.1. Global Hemophilia A Treatment Market, by Specialty Pharmacies, by Region, 2020-2034 (USD Billion)

8. Global Hemophilia A Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Hemophilia A Treatment Market Assessment, b y Geography, 2020-2034 (USD Billion)
  • 8.3. Hemophilia A Treatment Market - North America
    • 8.3.1. North America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.3.2. North America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.3.3. North America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.4. Hemophilia A Treatment Market - US
      • 8.3.4.1. US: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.3.4.2. US : Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.4.3. US : Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.5. Hemophilia A Treatment Market - Canada
      • 8.3.5.1. Canada: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4. Hemophilia A Treatment Market - Europe
    • 8.4.1. Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.4. Hemophilia A Treatment Market - UK
      • 8.4.4.1. UK: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.5. Hemophilia A Treatment Market - France
      • 8.4.5.1. France: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.6. Hemophilia A Treatment Market - Germany
      • 8.4.6.1. Germany: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.7. Hemophilia A Treatment Market - Italy
      • 8.4.7.1. Italy: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.8. Hemophilia A Treatment Market - Spain
      • 8.4.8.1. Spain: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.9. Hemophilia A Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.10. Hemophilia A Treatment Market - Russia
      • 8.4.10.1. Russia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.11. Hemophilia A Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5. Hemophilia A Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.4. Hemophilia A Treatment Market - China
      • 8.5.4.1. China: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.5. Hemophilia A Treatment Market - India
      • 8.5.5.1. India: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.6. Hemophilia A Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.7. Hemophilia A Treatment Market - Japan
      • 8.5.7.1. Japan: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.8. Hemophilia A Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.9. Hemophilia A Treatment Market - South Korea
      • 8.5.9.1. South Korea: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.10. Hemophilia A Treatment Market - Australia
      • 8.5.10.1. Australia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.11. Hemophilia A Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6. Hemophilia A Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.4. Hemophilia A Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.5. Hemophilia A Treatment Market - UAE
      • 8.6.5.1. UAE: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.6. Hemophilia A Treatment Market - Israel
      • 8.6.6.1. Israel: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.7. Hemophilia A Treatment Market - South Africa
      • 8.6.7.1. South Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.8. Hemophilia A Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7. Hemophilia A Treatment Market - Latin America
    • 8.7.1. Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.4. Hemophilia A Treatment Market - Mexico
      • 8.7.4.1. Mexico: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.5. Hemophilia A Treatment Market - Brazil
      • 8.7.5.1. Brazil: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.6. Hemophilia A Treatment Market - Argentina
      • 8.7.6.1. Argentina: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.7. Hemophilia A Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. CSL Behring
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Novo Nordisk A/S
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Takeda Pharmaceutical Company Limited
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bayer AG
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sanofi (through its acquisition of Bioverativ)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. F. Hoffmann-La Roche Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Octapharma AG
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Grifols S.A.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. BioMarin Pharmaceutical Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Spark Therapeutics (a subsidiary of Roche)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Aptevo Therapeutics
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Kedrion Biopharma
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Sangamo Therapeutics
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. uniQure N.V.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development